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Abstract
Background: The $1.1 billion investment in comparative effectiveness research will reshape the evidence-base supporting
decisions about treatment effectiveness, safety, and cost. Defining the current prevalence and characteristics of comparative
effectiveness (CE) research will enable future assessments of the impact of this program.
Methods: We conducted an observational study of clinical trials addressing priority research topics defined by the Institute
of Medicine and conducted in the US between 2007 and 2010. Trials were identified in ClinicalTrials.gov. Main outcome
measures were the prevalence of comparative effectiveness research, nature of comparators selected, funding sources, and
impact of these factors on results.
Results: 231 (22.3%; 95% CI 19.8%–24.9%) studies were CE studies and 804 (77.7%; 95% CI, 75.1%–80.2%) were non-CE
studies, with 379 (36.6%; 95% CI, 33.7%–39.6%) employing a placebo control and 425 (41.1%; 95% CI, 38.1%–44.1%) no
control. The most common treatments examined in CE studies were drug interventions (37.2%), behavioral interventions
(28.6%), and procedures (15.6%). Study findings were favorable for the experimental treatment in 34.8% of CE studies and
greater than twice as many (78.6%) non-CE studies (P,0.001). CE studies were more likely to receive government funding
(P = 0.003) and less likely to receive industry funding (P = 0.01), with 71.8% of CE studies primarily funded by a
noncommercial source. The types of interventions studied differed based on funding source, with 95.4% of industry trials
studying a drug or device. In addition, industry-funded CE studies were associated with the fewest pediatric subjects
(P,0.001), the largest anticipated sample size (P,0.001), and the shortest study duration (P,0.001).
Conclusions: In this sample of studies examining high priority areas for CE research, less than a quarter are CE studies and
the majority is supported by government and nonprofits. The low prevalence of CE research exists across CE studies with a
broad array of interventions and characteristics.
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Introduction
Comparative effectiveness (CE) research is the ‘‘generation and
synthesis of evidence that compares the benefits and harms of
alternative methods to prevent, diagnose, treat and monitor health
conditions in ‘real world’ settings’’.[1] Recognizing that the
evidence-base for the practice of medicine is often built on studies
lacking active comparators and therefore falls short in supporting
either high quality care or healthcare reform, there is now
substantial focus on and investment in CE research.[2] In the
United Kingdom, for instance, the National Institute for Health
and Clinical Excellence compiles and disseminates CE and cost-
effectiveness data to support diagnostic and therapeutic deci-
sions.[3,4] Similar agencies in Canada and Australia—the
Common Drug Review and the Pharmaceutical Benefits Advisory
Committee, respectively—provide information on the effectiveness
and cost of pharmaceuticals, specifically, compared to relevant
alternatives.[5,6,7]
In the United States, CE research was recently appropriated
$1.1 billion through the American Recovery and Reinvestment
Act of 2009.[1,8] This funding reflects the growing awareness that
improved data is needed on the relative benefits of therapies to
enable patients and clinicians to make informed decisions and to
reduce gross geographic variations in healthcare allocations seen
across the United States.[9,10]
In order to envision how the evolution of CE research will shape
the evidence-base for future healthcare delivery, we sought to
leverage a novel data source of clinical trials—the web-based
registry ClinicalTrials.gov—and measure the prevalence of CE
research and characterize current CE research activity. We focus
our empirical study on research conducted in the United States
where the concerted effort to expand CE research has not yet had
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a substantial impact on studies performed. Specifically, we
examine research areas highlighted in the 2009 Institute of
Medicine (IOM) list of 100 priority topics deemed to be most
pertinent to improving the health of the population, commissioned
by the United States Congress to inform the initial investment in
CE research.[11] Since we focus on research activity in the United
States, we limit our study to trials registered in ClinicalTrials.gov,
which is the primary registry employed by investigators in the
United States and which has previously been used to define and
study large trial cohorts.[12,13] To begin to anticipate the impact
of the investment in CE research, we determine the prevalence of
CE research to date, the types of interventions studied, and the
role of funding sources sponsoring CE research.
Methods
Selection of Clinical Studies
We examined the 15 research areas among the top 25 topics on
the IOM list of priority areas that addressed specific diseases or
conditions as opposed to strategies for delivering care or diagnostic
and treatment approaches for broad groups of conditions (Table
S1).[11] We identified studies pertaining to these research areas in
ClinicalTrials.gov, selecting trials that were registered between
January 1, 2007 and April 26, 2010 (date of data download from
ClinicalTrials.gov) and that were conducted in the United States
(Figure 1).
ClinicalTrials.gov is a web-based registry of clinical studies that
provides a publicly available source of information on clinical
studies conducted in the United States and internationally.[14] In
2005, the International Committee of Medical Journal Editors
instituted a policy requiring prospective registration of all trials—
regardless of intervention type—as a prerequisite for publication,
resulting in a dramatic increase in the registration of trials and
sustained wide-spread use since then.[15,16] In addition, under
the FDA Amendments Act of 2007, the FDA requires the
registration in ClincialTrials.gov of all clinical investigations
(except phase I trials) of a drug, biologic, or device that is subject
to FDA regulation, regardless of trial design.[17] Users can query
the registry and identify specific types of trials using a search
function that includes keyword searches. We employed keywords
identified from published systematic reviews on the diseases or
conditions of interest (Table S1). Studies selected using this search
Figure 1. Study Flow Diagram. Selection of trials in ClinicalTrials.gov that address 15 research topics identified by the Institute of Medicine as
being top priority for comparative effectiveness research.
doi:10.1371/journal.pone.0028820.g001
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strategy were individually reviewed and those included that
directly addressed the research topics of interest.
Definitions and Data Extraction
CE studies were defined as those comparing the experimental
intervention to another active therapy as opposed to a placebo
control or no comparator.[18] Both the experimental treatment
and the comparator were classified as an intervention involving a
drug, device, procedure, behavioral change, or other treatment
(e.g. dietary supplement). Active comparator studies were defined
as studies that compared two treatment alternatives, including
‘‘optimal usual care’’ when these reflected appropriate current
practice and standards.[2,11] In determining the type of
comparator employed, we did not rely on the investigator-assigned
study labels in ClinicalTrials.gov but rather examined the detailed
description of the study in the record.
The data elements obtained from the ClincialTrials.gov entry
and recorded for each study were registration date, study start and
completion dates, experimental treatment under study, compar-
ator type, trial phase for drug and device studies, funding source,
outcome measures, anticipated enrollment number, subject age
groups, and elements of the study design.
Study outcome measures are specifically listed in the study
record as primary and secondary outcomes and we determined
whether these included measures of safety, including any side
effects, adverse events, or other potential harms or risks related to
the intervention, or cost assessments, including formal cost-
analyses and general measures of resource utilization. For 17
studies that did not include specific outcome measures in the study
record, we reviewed the study descriptions to identify the inclusion
of safety and cost assessments.
Funding source was classified as government, industry, or
nonprofit based on the funding sponsors listed in the record. We
categorized ‘‘NIH’’, ‘‘U.S. federal’’, and ‘‘other government’’ as
government funding; ‘‘industry’’ as industry funding; and
‘‘network’’, ‘‘individual’’, and ‘‘other’’ (which includes universities,
hospitals, foundations, and other nonprofit organizations) as
nonprofit funding.[12] We applied this classification to primary
and secondary funding sources. Subject ages are categorized in the
registry as ‘‘Child’’ (up to 17 years), ‘‘Adult’’ (18 to 65 years),
‘‘Senior’’ (66 years and older), and combinations of these groups.
We re-coded these data into a three-level variable of children only,
children and adults/seniors, and adults/seniors.
Classification of experimental intervention, comparator type,
and safety and cost assessments were performed independently by
two of the authors (F.B. and S.M.) and disagreements resolved by
consensus.
Assessment of Study Outcomes
Publications associated with studies were identified using a
previously described method.[12] Briefly, for studies that did not
include results or a reference to a publication within the
CinicalTrials.gov record, four electronic databases were searched.
These included PubMed, the Cochrane Library, EMBASE, and
the Cumulative Index to Nursing and Allied Health Literature
(CINAHL). All searches were finalized by August 31, 2010. Each
publication was reviewed and the results for the primary outcome
classified as favorable (i.e. statistically significant based on P values
or confidence intervals) or not favorable (i.e. not statistically
significant) for the experimental treatment. For studies without a
comparator or statistical analysis, the classification was based on
the interpretation of the results provided in the study conclusions.
Publications that did not describe results pertaining to the efficacy
or safety of the intervention were classified as ‘‘neither’’. Two of
the authors (F.B. and S.M.) independently performed the outcome
classification and resolved disagreements by consensus. Inter-coder
agreement for assigning study outcomes was good with a kappa of
0.78 (95% CI, 0.65–0.91).
Statistical Analysis
We calculated the proportion of studies that were CE studies
and compared study characteristics for CE and non-CE studies.
Sub-analyses were performed on CE studies based on funding
source. Trials examining a pharmaceutical intervention were also
specifically examined and CE and non-CE studies compared. Chi-
square and Kruskal-Wallis tests were used to compare categorical
and median values, respectively. We used the Cochran-Mantel-
Haenszel test to control for funding source when examining study
outcomes. All data were analyzed with SAS software (version 9.2,
SAS Institute Inc., Cary, North Carolina).
Results
Of the 3167 studies retrieved from ClinicalTrials.gov, 1035
were included in the final study sample after reviewing the study
description (Figure 1). Among these, 231 (22.3%; 95% confidence
interval [CI], 19.8%–24.9%) were CE studies and 804 (77.7%;
95% CI, 75.1%–80.2%) were non-CE studies, with 379 (36.6%;
95% CI, 33.7%–39.6%) employing a placebo control and 425
(41.1%; 95% CI, 38.1%–44.1%) no control.
Study characteristics are presented in Table 1. In half the
studies examined (49.9%), the experimental treatment consisted of
a pharmacological therapy and in 18.3% a behavioral interven-
tion. The distribution of experimental treatments differed for the
different study types, with drug treatments more likely to be
studied with a placebo or no intervention (P,0.001). Studies with
active comparators were more likely to be in advanced phases
(Phase 3 or 4; P,0.001), to employ larger sample sizes (P,0.001),
and to be longer in duration (P= 0.02). Fewer studies with active
comparators included a primary safety outcome (8.2% vs. 14.0%
and 23.8% for placebo-controlled and no comparator studies;
P,0.001) and only 3.5% included a cost assessment.
Impact of Funding Source on Characteristics of CE
Studies
The distribution of primary funding sources was similar among
CE and non-CE studies (Table 2). Overall, 71.8% (n= 166) of CE
studies were funded by non-commercial sources, including
government and nonprofit organizations. CE studies were more
likely to include government funding (32.5% compared with
22.9% of non-CE studies, P= 0.003) and less likely to include
industry funding (37.2% compared with 46.4% of non-CE studies,
P= 0.01).
We further examined study interventions and other character-
istics for CE studies based on funding source (Table 3). Among CE
studies funded primarily by industry, 95.4% involved the study of
a drug or device and most compared the intervention to another
drug or device (90.8%). Primarily industry-funded CE studies
involved the largest anticipated sample size (median of 324
subjects vs. 175 and 100 subjects for government and nonprofit
funding, respectively; P,0.001), were the least likely to enroll
pediatric subjects (7.6% vs. 37.5% and 17.3% for government and
nonprofit funding, respectively; P,0.001), and were the shortest in
duration (median length 1.8 years vs. 3.0 and 2.4 years for
government and nonprofit funding, respectively; P,0.001).
Studies with any type of government funding were less likely to
study a drug or device (P,0.001) and more likely to include
children (P,0.001) and be longer in duration (P,0.001).
Comparative Effectiveness Research Trials
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Government funding was not associated with an increase in the
study of safety or cost outcomes.
Pharmaceutical and Device Studies and CE Research
Among the subset of 516 studies examining a pharmaceutical
intervention, 86 (16.7%; 95% CI, 13.4%–19.9%) were CE studies
and 430 (83.3%; 95% CI, 80.1%–86.6%) were non-CE studies.
Government sources provided primary funding for 11.6%
(n= 10) and industry for 52.3% (n= 45) of CE drug studies
(Table 4). CE studies were less likely to include a safety outcome
compared with non-CE studies (P,0.001), involved larger
anticipated sample sizes (median of 238 subjects vs. 80 subjects;
P,0.001), and were less likely to be double-blinded (66.7% vs.
92.7%; P,0.001). Device studies included 32 (26.4%; 95% CI,
Table 1. Comparative Effectiveness Studies Registered in ClinicalTrials.gov.
Characteristic Category Total (n = 1035) Study Type
Comparative
Effectiveness Study:
Active Comparator
(n =231)
Non-Comparative
Effectiveness Study:
Placebo Control
(n= 379)
Non-Comparative
Effectiveness Study:
No Control (n= 425)
Experimental treatment, n (%)a Drug 516 (49.9) 86 (37.2) 226 (59.6) 204 (48.0)
Device 121 (11.7) 32 (13.8) 27 (7.1) 62 (14.6)
Procedure 146 (14.1) 36 (15.6) 22 (5.8) 87 (20.5)
Behavioral change 189 (18.3) 66 (28.6) 77 (20.3) 46 (10.8)
Other 48 (4.8) 11 (4.8) 26 (6.9) 11 (2.6)
None 15 (1.4) 0 0 15 (3.5)
Study phase, n (%) b, c Phase 1, 2, 2/3 275 (43.2) 40 (33.9) 105 (41.2) 131 (49.2)
Phase 3, 4 230 (36.1) 52 (44.1) 101 (39.6) 78 (29.3)
Unknown 132 (20.7) 26 (22.0) 49 (19.2) 57 (21.4)
Primary safety outcome, n (%)a Yes 173 (16.7) 19 (8.2) 53 (14.0) 101 (23.8)
Cost assessment, n (%) Yes 24 (2.3) 8 (3.5) 11 (2.9) 5 (1.2)
Anticipated sample size, median
(IQR Q1,Q3) a,e
100 (40, 280) 160 (78, 350) 147 (56, 327) 60 (30, 164)
Age of study population, n (%)a Children only 171 (16.5) 40 (17.3) 50 (11.8) 81 (21.4)
Children and adults 124 (12.0) 29 (12.6) 42 (9.9) 53 (14.0)
Adults only 740 (71.5) 162 (70.1) 333 (78.4) 245 (64.6)
Length of study, median
years (IQR Q1,Q3) c, f
2.1 (1.1, 3.3) 2.4 (1.4, 3.7) 2.0 (1.0, 3.2) 2.0 (1.0, 3.2)
Abbreviations: IQR, interquartile range.
aP,0.001 for chi-square and Kruskal-Wallis tests for categorical and median values, respectively.
bPhase data applies to 637 drug and device trials.
cP = 0.02 for chi-square.
dRandomization applies to 610 trails with an active comparator or placebo control.
eSample size data available for 1025 trials.
fStudy length available for 860 trials.
doi:10.1371/journal.pone.0028820.t001
Table 2. Funding Sources for Comparative Effectiveness and Non-Comparative Effectiveness Studies Registered in
ClinicalTrials.gov.
Characteristic Category Total (n =1035), n (%) Study Type P-value
Comparative
Effectiveness Study
(n =231), n (%)
Non-Comparative
Effectiveness Study
(n =804), n (%)
Primary funding source Government 110 (10.6) 32 (13.8) 78 (9.7) 0.10
Industry 334 (32.3) 65 (28.1) 269 (33.5)
Nonprofit 591 (57.1) 134 (58.0) 458 (57.0)
Government funding All or some government funding 259 (25.0) 75 (32.5) 184 (22.9) 0.003
No government funding 776 (75.0) 156 (67.5) 620 (77.1)
Industry funding All or some industry funding 459 (44.4) 86 (37.2) 373 (46.4) 0.01
No industry funding 576 (55.6) 145 (62.8) 431 (53.6)
doi:10.1371/journal.pone.0028820.t002
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18.6%–34.3%) CE studies and 89 (73.6%; 95% CI, 65.7%–
81.4%) non-CE studies. Government was the primary funding
source for 6.2% (n= 2) and industry 53.1% (n= 17) of the CE
device studies.
CE Study Outcomes
Results were identified for 115 (11.1%) studies. A total of 8/23
(34.8%) reports described positive findings for studies with active
controls compared with 66/84 (78.9%) among non-CE studies
(12/32 [73.9%] placebo-controlled trials and 6/32 [84.2%] trials
without controls) (P,0.001). Among trials primarily funded by
industry, 33/41 (80.5%) reported positive findings compared with
41/66 (61.7%) among all others (P = 0.04). After controlling for
primary funding source, CE studies remained less likely to report
positive findings (P,0.007 for Cochran-Mantel-Haenszel test).
Among CE studies involving a drug therapy, findings were
positive for 30.0% (n= 3) of CE studies compared with 81.6%
(n= 40) of non-CE studies (P,0.001, Cochran-Mantel-Haenszel
test controlling for primary funding source). None of the CE
studies examining devices and 71.4% (n= 5) of non-CE studies
involving devices reported findings favorable for the device
(P = 0.04).
Discussion
We provide a benchmark for the current state of CE research,
demonstrating that for conditions deemed as highest priority by
the IOM, less than a quarter of studies examined compara-
tive effectiveness. The majority of CE studies were funded by
government and nonprofit sources and outcomes were less likely to
be positive for the experimental intervention among CE trials
compared with non-CE trials. Funding sources had a substantial
impact on the characteristics of CE studies, with industry-funded
trials focusing primarily on drugs and devices and those funded by
noncommercial sources addressing more diverse types of inter-
ventions. Industry-funded trials also differed in trial design with
larger sample sizes, fewer studies involving pediatric patients, and
shorter study periods.
Table 3. Characteristics of Comparative Effectiveness Studies by Funding Source.
Characteristic Category
Total
(n = 231) Primary Funding Source Government Funding
Government
(n =32)
Industry
(n =65)
Nonprofit
(n = 134) P-value
All or Some Govern-
ment (n=75)
No Government
(n=156) P -value
Experimental
treatment, n
(%)
Drug 86 (37.2) 10 (31.2) 45 (69.2) 31 (23.1) ,0.001 19 (25.3) 67 (43.0) ,0.001
Device 32 (13.8) 2 (6.2) 17 (26.2) 13 (9.7) 3 (4.0) 29 (18.6)
Procedure 36 (15.6) 1 (3.1) 2 (3.1) 33 (24.6) 9 (12.2) 27 (17.3)
Behavioral change 66 (28.6) 18 (56.2) 1 (1.5) 47 (35.1) 40 (53.3) 26 (16.7)
Other 11 (4.8) 1 (3.1) 0 10 (7.5) 4 (5.3) 7 (4.5)
Comparison
type, n (%)
Drug vs. drug 76 (32.9) 8 (25.0) 46 (70.8) 22 (16.4) ,0.001 14 (18.7) 62 (39.7) ,0.001
Device vs. device 27 (11.7) 2 (6.2) 13 (20.0) 12 (9.0) 3 (4.0) 24 (15.4)
Procedure vs.
procedure
29 (12.6) 1 (3.1) 1 (1.5) 27 (20.2) 7 (9.3) 22 (14.1)
Behavioral change
vs. behavioral change
64 (27.7) 17 (53.1) 0 47 (35.1) 39 (52.0) 25 (16.0)
Other 35 (15.1) 4 (12.5) 5 (7.7) 26 (19.4) 12 (16.0) 23 (14.8)
Primary safety
outcome, n (%)
Yes 18 (7.8) 1 (3.1) 14 (21.5) 4 (3.0) ,0.001 2 (2.7) 17 (10.9) 0.03
Cost
assessment, n
(%)
Yes 8 (3.5) 0 1 (1.5) 7 (5.2) 0.21 2 (2.7) 6 (3.8) 0.65
Anticipated
sample size,
median (IQR
Q1,Q3) a
160
(80, 355)
175
(121, 288)
312
(205, 550)
100
(57, 240)
,0.001 160
(80, 300)
155
(61, 400)
0.65
Age of study
population, n
(%)
Children only 40 (17.3) 12 (37.5) 5 (7.7) 23 (17.2) ,0.001 22 (29.7) 18 (11.5) ,0.001
Children and adults 29 (12.6) 5 (15.6) 3 (4.6) 21 (15.7) 12 (16.2) 17 (10.9)
Adults only 162 (70.1) 15 (46.9) 57 (87.7) 90 (67.2) 41 (54.7) 121 (77.6)
Length of
study, median
years (IQR
Q1,Q3) b
2.4
(1.3, 3.7)
3.0
(2.4, 4.2)
1.9
(1.1, 2.7)
2.4
(1.7, 3.9)
,0.001 2.9
(2.2, 4.2)
2.2
(1.2, 3.0)
,0.001
aSample size data available for 229 trials.
bStudy length available for 199 trials.
doi:10.1371/journal.pone.0028820.t003
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Only a small proportion of CE studies address safety and cost
outcomes, highlighting an opportunity for government-sponsored
CE research to play a significant role. [2,19,20,21] Regardless of
funding source, CE studies are less likely to examine safety
outcomes, particularly among drug studies, demonstrating an
emphasis on measuring treatment efficacy over measuring
treatment risks and adverse events. Cost assessments are currently
rare for both CE and non-CE studies across all funding sources.
Hochman et al previously found low prevalence of CE studies
and a higher rate of positive outcomes among non-CE studies of
pharmaceuticals compared with CE studies. [18] Using a
comprehensive and growing data source of recent and ongoing
research activity, our results corroborate those findings. We
further demonstrate that the low prevalence of CE research and
differences in outcomes exist across CE studies with a broad array
of interventions and that characteristics of CE studies vary
substantially based on the funding source sponsoring the study.
With an ever-expanding list of diagnostic and therapeutic
options, CE studies fill an important gap in informing clinicians
whether an intervention is superior to existing and familiar
alternatives. Our findings suggest characteristics of CE research
that may produce specific shifts in the evidence-base towards more
critical and comprehensive assessments of the intervention under
study. From our findings, we extrapolate that the projected
increase in the number of CE studies—particularly studies of drugs
and devices funded by noncommercial sources—will increase the
proportion of studies that fail to support adoption of the
experimental treatment. We base this prediction on two findings.
The first is that CE studies are less likely than non-CE studies to
report results that promote the use of the experimental
intervention, reinforcing that this study design may produce more
conservative results in terms of the superiority of a therapy
compared to other treatments. Trials with inactive comparators
have previously been shown to have a greater likelihood of
achieving favorable findings.[18,22,23] Drug and device studies
that employ non-active comparators and yield favorable outcomes
may encourage the adoption and use of the experimental
intervention even though information is lacking on how the drug
or device compares to current standards of care.[23]
Secondly, while noncommercial sources funded 71% of CE
studies overall, industry funded the majority of CE drug and
device studies, which biases toward results supporting the use of a
product.[24,25,26,27] Industry trials investigating drugs and
devices are typically designed and conducted by the company
marketing the product and there is substantial and well-
documented evidence that these studies are more likely to report
findings supporting the efficacy and safety of the product than
noncommercially funded studies.[12,24,25,28,29,30] In our study
sample, industry-funded studies were more likely to report an
outcome favoring the use of the intervention than noncommer-
cially-funded studies, and only 17% of drug studies and 26% of
device studies used an active comparator. Research on drugs and
Table 4. Study Characteristics of Drug Trials Registered in ClinicalTrials.gov.
Characteristic Category Total (n = 516) Trial Type P-value
Comparative
Effectiveness Trial
(n = 86)
Non-Comparative
Effectiveness Trial
(n = 430)
Primary funding source, n (%) Government 36 (7.0) 10 (11.6) 26 (6.0) 0.11
Industry 260 (50.4) 45 (52.3) 215 (50.0)
Nonprofit 220 (42.6) 31 (36.0) 189 (44.0)
Study phase, n (%) Phase 1, 2, 2/3 247 (47.9) 37 (43.0) 210 (48.8) 0.58
Phase 3, 4 193 (37.4) 36 (41.9) 157 (36.5)
Unknown 76 (14.7) 13 (15.1) 63 (14.6)
Primary safety outcome, n (%) Yes 119 (23.1) 7 (8.1) 112 (26.0) ,0.001
Cost assessment, n (%) Yes 12 (2.3) 3 (3.5) 9 (2.1) 0.43
Study design: observational vs.
interventional, n (%)
Observational 10 (1.9) 2 (2.3) 8 (1.9) 0.78
Randomization, n (%) a Yes 297(95.2) 81 (94.2) 216 (95.6) 0.61
Blinding, n (%) b Double-blind 256 (86.2) 54 (66.7) 202 (92.7) ,0.001
Single-blind 9 (3.0) 6 (7.4) 3 (1.4)
No blinding 32 (10.8) 21 (25.9) 11 (5.1)
Anticipated sample size, median
(IQR Q1,Q3) c
100 (36, 292) 238 (90, 508) 80 (30, 255) ,0.001
Age of study population, n (%) Children only 83 (16.1) 12 (14.0) 71 (16.5) 0.71
Children and adults 34 (6.6) 7 (8.1) 27 (6.3)
Adults only 399 (77.3) 67 (77.9) 332 (77.2)
Length of study, median years
(IQR Q1,Q3) d
1.6 (0.9, 2.9) 2.0 (1.1, 2.7) 1.6 (0.8, 2.9) 0.30
Abbreviations: IQR, interquartile range.
aApplies to 312 trials with an active or placebo control.
bApplies to 297 trials that were randomized.
cSample size data available for 511 trials.
dStudy length available for 423 trials.
doi:10.1371/journal.pone.0028820.t004
Comparative Effectiveness Research Trials
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devices would benefit from greater participation of non-stakehold-
ers—such as government sponsors—as well as greater oversight in
study design in order to ensure rigorous and valid assessments of
the effectiveness of these treatments.[31]
There are several factors critical to ensuring the success of the
new CE research initiative and the ability of CE research to
improve clinical decision-making. Methodologically, CE studies
must be large enough and have a sufficient patient follow up
period to demonstrate not only equivalence, but superiority of one
treatment compared to another.[32] Randomized controlled trials,
which are typically designed to ascertain the efficacy of an
intervention in select patient populations and tightly controlled
settings, may not reflect real-world outcomes or be generalizable to
routine clinical practice, which is one of the defining principles of
CE research. By contrast, pragmatic clinical trials and observa-
tional studies may provide results that are directly pertinent to
clinicians and patients choosing between available therapies.[33]
In addition, comparative efficacy data must be timely and
available prior to the widespread adoption of new products or
interventions, as the lack of comparative evidence has resulted in
the extensive use of a number of treatments later found to be less
efficacious or safe than existing alternatives.[20,31]
A limitation of our study is that outcomes data are not available
for all studies since we chose to examine recent and ongoing
studies, in order to ensure that our findings are most pertinent to
the current state of CE research. However, it is unlikely that
systematic bias produced our finding that CE studies are more
likely to yield favorable outcomes. This finding is supported in
prior literature and the sample of published results is of sufficient
magnitude to demonstrate important and statistically significant
differences in reported outcomes. [18,22] We were not able to
verify the accuracy of data provided by investigators, but
information such as experimental treatment, comparator type,
and funding source, are likely properly and reliably reported.
Finally, there are some missing data in ClincialTrials.gov,
including anticipated sample size for 1% of trials and study
duration for 17% of trials.
In conclusion, less than a quarter of studies use an active
comparator to measure the CE of the treatment under
investigation. Based on outcomes reported in CE and non-CE
studies, CE studies in general appear to provide more rigorous
assessments of the interventions under study. Boosting noncom-
mercial funding of CE studies may be particularly critical to drug
and device studies in order to ensure unbiased data on how the
intervention compares to other available treatments. Further study
is necessary to understand the impact of CE research on
healthcare reform and cost, as there is a risk when new treatments
face a higher barrier to acceptance that some innovation may be
slowed and development costs increased. On the other hand, we
can expect that CE research will provide physicians and patients
with substantially stronger evidence about which therapies are
effective.
Supporting Information
Table S1 Study Topics and Keywords for Study Selec-
tion. Clinical trials examined in the study pertained to these 15
research areas. The corresponding keywords were used to identify
the trials in ClinicalTrials.gov using the embedded search
function.
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